Viewing nowCombinationRosuvastatin/ValSartan Tablets 20/160 mg
Rosuvastatin Calcium 20.8mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Korea Hutex Pharmaceutical Co., Ltd.

MFDS item code 202003910 · Approved 2020.05.27
Improvement of dyslipidemia; treatment of hypertension and heart failure; prevention of atherosclerosis and cardiovascular risk
This medication is used for patients who need both valsartan and rosuvastatin. Valsartan primarily helps treat essential hypertension and heart failure, and reduce the risk of death after myocardial infarction. It is particularly used in heart failure patients who are intolerant to ACE inhibitors. Rosuvastatin is used as an adjunct when dietary changes and exercise cannot adequately control hyperlipidemia and is effective in slowing the progression of atherosclerosis. It also helps reduce the risks of stroke, myocardial infarction, and arterial revascularization in patients with high cardiovascular risk. Therefore, this drug is used to effectively improve hypertension and dyslipidemia.
This medicine is intended for adults only. The dosage should be individualized for each patient based on the efficacy and tolerability of each component, valsartan and rosuvastatin. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be co-administered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When co-administered with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Thereafter, over several weeks, the dose should be increased, taking the patient's tolerability into consideration, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dosage adjustment is necessary if creatinine clearance is 10 mL/min or greater. However, as there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medicine. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If doses of 80 mg or more per day are administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if greater reductions in LDL cholesterol are needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more, according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 milligrams once daily. 2. Older adults: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking valsartan and rosuvastatin concomitantly, treatment may be switched to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.
This drug can cause severe harm to the fetus during pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Women who are pregnant or may become pregnant, and breastfeeding women should not take this medication. Patients with severely impaired liver function or certain liver diseases should not use this medication. Patients with muscle diseases or a history of muscle problems related to similar medications should also avoid taking it. Patients with severe kidney impairment are also advised not to use this medication. Caution should be exercised in elderly patients or those with high blood potassium levels. Patients with heart diseases or dehydration should also be cautious when taking this medication. This drug may cause muscle pain, weakness, and, rarely, severe muscle damage (rhabdomyolysis), thus medical consultation should be sought immediately if muscle pain or weakness occurs. Liver function tests are recommended before and during treatment as liver function problems may develop. It is advisable to avoid or limit alcohol intake during treatment. There may be interactions when taking this medication with other drugs, so inform healthcare providers of any other medications being taken. This medication is not used in children and adolescents as safety and efficacy have not been established. There is no specific antidote for overdose, so seek medical care immediately if symptoms occur. This medication should be kept out of reach of children and should not be transferred to another container.
Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, weakness, chest pain, facial edema, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased serum liver aminotransferase (AST, ALT) levels, elevated serum creatine phosphokinase, increased serum potassium, elevated gamma-glutamyl transferase, musculoskeletal stiffness, limb pain, sensory disturbance, anxiety, upper respiratory infection, pharyngitis, tonsillitis, spinal canal stenosis, aphasia, oral hemorrhage, vomiting, insulin-dependent diabetes mellitus, diabetes complications, leg fracture, spinal fracture, fracture, skin tumor, second-degree atrioventricular block, vestibular neuritis, retinal detachment, undefined skin tumor-like condition, shingles, intervertebral disc herniation, hemoptysis, sputum disease, bronchitis, sensory abnormalities, hoarseness, gastroesophageal reflux, diverticulitis, stomatitis, gastritis, carpal tunnel syndrome, chills, facial flushing, increased blood sugar, elevated triglycerides, increased blood pressure, exacerbation of hypertension, neck/shoulder pain, toe fracture, osteomyelitis, skin infection, undefined dermatitis, localized skin reaction, palpitations, exacerbation of angina, auditory disturbances, overactive bladder, elevated serum creatinine, vitreous detachment, benign prostatic hyperplasia, laceration, headache, dizziness, constipation, abdominal pain, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, shortness of breath, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, eosinophilia with systemic symptom drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorder, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia, hypotension, orthostatic dizziness, orthostatic hypotension, renal function damage, hyperkalemia, angioedema, redness, itching, serum sickness, vasculitis, syncope, epistaxis, interstitial pneumonia, hypoglycemia, shock, loss of consciousness, agranulocytosis, leukopenia, thrombocytopenia, reduced red blood cell volume, reduced hemoglobin, edema, weakness, insomnia, redness, decreased libido, dizziness, acute renal failure, myalgia, myopathy, myositis, rhabdomyolysis, increased transaminases
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a container that shields it from light and prevents air from entering, preferably at room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain its efficacy for a longer period.
Brown oval film-coated tablet
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationRosuvastatin Calcium 20.8mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Korea Hutex Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Rosuvastatin Calcium 20.8mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Medika Korea Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Medica Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.